1	completion of ux007g-cl201 study nct 01993186 in the past 3 month patient who receive ux007/triheptanoin treatment a apart of clinical study ists or expand access/compassionate use treatment program may be eligible at the discretion of the sponsor|triheptanoin[92,104]|||||||3 month[58,65]|||1313234|1313234|triheptanoin
